| Charles Ronald Smalling Jr, MD | |
|
2131 E State St, Athens, OH 45701-2138 | |
| (740) 589-3100 | |
| (740) 566-4049 |
| Full Name | Charles Ronald Smalling Jr |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 2131 E State St, Athens, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144203092 | NPI | - | NPPES |
| 2723815 | Medicaid | OH | |
| 3810007810 | Medicaid | WV | |
| 2723815 | Other | OH | OH MEDICAID MOLINA |
| P00362716 | Other | OH | RAILROAD MEDICARE |
| 000000204802 | Other | OH | OH MEDICAID UNISON |
| 310917085159 | Other | OH | OH MEDICAID CARESOURCE |
| Mailing Address | Practice Location Address |
|---|---|
| Charles Ronald Smalling Jr, MD 90 Jackson Pike, Gallipolis, OH 45631-1560 Ph: (740) 589-3100 | Charles Ronald Smalling Jr, MD 2131 E State St, Athens, OH 45701-2138 Ph: (740) 589-3100 |
News Archive
A physician's personality can affect practice behavior in inquiries about patient mood symptoms and the diagnosis of depression, according to a study led by University of Rochester Medical Center researchers.
ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.
New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.
MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.
› Verified 7 days ago
Dr. Chase Andrew Scarbrough, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 55 Hospital Dr, Athens, OH 45701 Phone: 740-592-9334 | |
Kasie Kudrewicz Adkins, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2111 E State St, Athens, OH 45701 Phone: 740-566-4621 | |
Sarah M Croft, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2111 E State St, Athens, OH 45701 Phone: 740-566-4621 | |
Dr. Elizabeth M Naylor, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2111 E State St, Athens, OH 45701 Phone: 740-566-4621 Fax: 740-566-4622 | |
Dr. Dawn Lynnette Merritt, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2111 E State St, Athens, OH 45701 Phone: 740-566-5621 Fax: 740-566-4622 | |
Harry L Winfield, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2111 E State St, Athens, OH 45701 Phone: 740-566-4621 Fax: 740-566-4622 |